Cutting-edge Biology: Sign a licensing agreement with GlaxoSmithKline, with a payment of up to 9.5 billion US dollars.

Frontier Bioscience announced that on February 16, 2026, it signed an agreement with GlaxoSmithKline, granting them exclusive global development rights to two small nucleic acid pipeline products, with each candidate drug in the IND stage and preclinical stage, respectively. The company will receive an upfront payment of $40 million and a near-term payment of $13 million, with the potential to receive up to a total of $950 million in milestone payments, as well as tiered royalties on global net sales. The company will be responsible for early development, while GlaxoSmithKline will be responsible for subsequent global activities. The transaction does not constitute a significant asset reorganization and has been approved by the board of directors. This partnership may improve cash flow, but there are risks associated with product approval and commercialization.